Prostate Cancer

A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease. The non-invasive test is less painful and cheaper than tissue biopsies and can help pick out men who are less likely to respond at the start of treatment, or those more likely to relapse later on. This type of blood test, known as a liquid biopsy, could drive more precise patient care – allowing clinicians to tailor treatment for men with advanced prostate cancer, and to stop drugs that are unlikely to work as quickly as possible. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust analysed traces of cancer DNA that had entered the bloodstream to assess the ability of liquid biopsies to inform and guide treatment of advanced prostate cancer. The research, presented today (Friday) at the American Society of Clinical Oncology (ASCO) virtual annual me

(UroToday.com) Management of patients with de novo metastatic prostate cancer has rapidly evolved in the past few years. Numerous systemic therapies have been shown to prolong survival including docetaxel, abiraterone, enzalutamide, and apalutamide. Additionally, two trials (the multi-arm, adaptive STAMPEDE trial and the HORRAD trial) have demonstrated improvements in overall survival for men with a low burden of metastatic disease who receive cytoreductive local radiotherapy, compared to systemic therapy alone. There are a number of ongoing trials assessing the role of cytoreductive prostatectomy, radiotherapy, and other ablative approaches. In this Poster session at the 2020 American Society of Clinical Oncology Virtual Annual Meeting, Dr. Connor and colleagues presented the design of the IP2-ATLANTA trial. This is a phase II, multicentre, three-arm randomised controlled trial using a positive comparator arm. Men with new histologically diagnosed, hormone sensitive, metastatic prost

(UroToday.com) For patients with high risk localized prostate cancer, 15-year prostate cancer survival ranges from 20-38%. However, unlike other tumor types where neoadjuvant therapy has been shown to improve overall survival outcomes (breast, bladder, rectal), there remains a paucity of randomized data showing improved long-term outcomes with neoadjuvant therapy for prostate cancer. Current NCCN, AUA, and ASCO guidelines do not recommend neoadjuvant therapy outside of a clinical trial. Prior studies, such as CALGB 90203 (Randomized patients to radical prostatectomy or neoadjuvant ADT + Docetaxel x 6 cycles followed by prostatectomy) did not show improvement in 3-year PSA PFS (Eastham et al, AUA 2019). More recently, neoadjuvant studies have been conducted with second-generation androgen antagonists such as abiraterone and enzalutamide, and this has demonstrated that 6 months of neoadjuvant ADT + enza can achieve pathologic complete response (CR) in some patients. 1 Prior analysis by

By Amy Norton HealthDay Reporter FRIDAY, May 29, 2020 (HealthDay News) -- For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke, a clinical trial has found. The drug, called relugolix, is not yet approved by the U.S. Food and Drug Administration. If it gets the green light, however, it would be "game-changing," said Dr. Neal Shore, lead researcher on the trial. Hormone therapy has long been a standard treatment for advanced prostate cancer -- including cases where the tumor has spread beyond the prostate gland or recurred after treatment with surgery or radiation. The goal is to suppress androgen hormones, including testosterone, because they fuel the growth of prostate tumors. Right now, that's usually done with injection drugs called LHRH agonists. The problem is that the drugs initially cause a surge in testosterone, before drastically cutting levels of

DelveInsight Business Research LLP This press release was orginally distributed by SBWire Albany, NY -- (SBWIRE) -- 05/29/2020 -- Prostate Cancer Market Insights, Epidemiology and Market Forecast-2030 (Albany, US) DelveInsight launched a new report on Prostate Cancer Market Insights, Epidemiology and Market Forecast-2030 Some of the key facts of the report 1. The total Prostate Cancer prevalent cases in the 7MM were observed to be 6,742,385 cases in 2017. 2. The highest number of prevalent cases of Prostate Cancer was observed in the United States with 3,170,339 cases in 2017. 3. In EU-5 countries, the highest number of diagnosed prevalent cases of Prostate Cancer was found in Germany with 360,916 cases in 2017. Key benefits of the report 1. Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Prostate Cancer epidemiology and Prostate Cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 2.

(UroToday.com) At the virtual AUA 2020 conference, nurse practitioner, Diane Newman, presented the problem of stress urinary incontinence (SUI) in men with prostate cancer (PCa) undergoing radical prostatectomy.  SUI is one of the most feared complications that has been shown to be an independent predictor of global quality of life (QOL). Prevalence ranges from 2 to 90%, but decreases over time.  Approximately 5–20% of men will continue to have some degree of incontinence 1–2 years after surgery.  A recent prospective, a population-based cohort study of 1386 men sought to determine functional outcomes associated with PCa treatments over 5 years after treatment. 4   Men undergoing prostatectomy surgery (RP) reported clinically meaningful worse incontinence through 5 years compared with all other options. Men undergoing prostatectomy for unfavorable-risk disease reported worse sexual function at 5 years compared with men who underwent external beam radiation therapy with androgen depriva

Read the Full Video Transcript Diane Newman : Welcome. I'm Diane Newman. I'm a continence nurse practitioner and a biofeedback-certified specialist. I'm also the Editor of the Bladder Health Center of Excellence on UroToday. I'm going to present to you a case study of a male patient who was referred to me for urinary symptoms following prostate cancer surgery. There's another recording that you can access on biofeedback-assisted pelvic floor muscle training, and this accompanies that because I do use biofeedback for pelvic floor muscle training, and I thought it might be helpful to walk through a case study of a patient who I see almost every day in my practice, so he's really a model for what you can do with these individuals. Most of these men present with stress urinary incontinence, and what I question is the characteristics of their urine leakage. Quantity is how much leaks. Snd patients don't walk around with a little bottle underneath their penis m

Until the recent FDA approval of rucaparib (Rubraca) for BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC), this patient population had no biomarker-driven therapies. But now the accelerated approval will bring a sea change to the prostate cancer space, while stressing the importance of genetic testing for men with high-risk and metastatic disease, according to Alan Bryce, MD. Bryce recently sat down with Oncology Nursing News ’ sister publication, OncLive , and discussed how the PARP inhibitor rucaparib is transforming the field. “This is an important moment in prostate cancer in that we finally have the fist approval for a biomarker-selected targeted therapy,” Bryce said. “We’ve known for some time that BRCA1/2 mutations in prostate cancer are predictors for efficacy to PARP inhibitors. Multiple studies have shown that. Now, we have [data] which led to the FDA approval of the PARP inhibitor rucaparib for use in patients with BRCA1/2-mutatnt mCRPC.” Adverse Events

By Serena Gordon HealthDay Reporter WEDNESDAY, May 20, 2020 (HealthDay News) -- Prostate cancer screening guidelines have been evolving for more than a decade, but new research suggests that recommendations against routine prostate cancer testing may have come at a steep price -- more men getting diagnosed with advanced prostate cancers. The study found that rates of advanced prostate cancers rose by about 5% per year through 2016. There was some good news, though. After routine use of the prostate specific antigen (PSA) test was no longer recommended for the majority of men, rates of early prostate cancer went down by 6.9% per year in men between 50 and 74 years old. (Early prostate cancers may be very slow-growing and may not need treatment.) "Men have to talk with their providers. They have to make sure they understand all of the benefits and harms of PSA testing. The benefits are that they may avoid advanced disease and may extend their life expectancy," said senio

Nearly one-third of men who have undergone treatment for prostate cancer report that a subsequent lack of sexual function has had the greatest impact on their quality of life, results from a new survey show. "All the studies have been saying that sexual function is okay after treatment, but we know that's not true," said André Deschamps, MBA, who is chair of the European Prostate Cancer Coalition, known as Europa UOMO. This issue has been neglected because people think older men aren't interested in sex, Deschamps told Medscape Medical News . "It makes me mad when people say a man in his 70s doesn't have a sexual life." That's not the case, he said. "Our study shows you a real picture of quality of life after treatment. We know it is affected far more heavily than the medical world has been telling us." The EUPROMS survey looked at quality of life in 2943 men, from 24 European countries, who had undergone some treatment for prostate ca

Nearly one-third of men who have undergone treatment for prostate cancer report that a subsequent lack of sexual function has had the greatest impact on their quality of life, results from a new survey show. "All the studies have been saying that sexual function is okay after treatment, but we know that's not true," said André Deschamps, MBA, who is chair of the European Prostate Cancer Coalition, known as Europa UOMO. This issue has been neglected because people think older men aren't interested in sex, Deschamps told Medscape Medical News . "It makes me mad when people say a man in his 70s doesn't have a sexual life." That's not the case, he said. "Our study shows you a real picture of quality of life after treatment. We know it is affected far more heavily than the medical world has been telling us." The EUPROMS survey looked at quality of life in 2943 men, from 24 European countries, who had undergone some treatment for prostate ca

Members of a large subset of prostate cancer patients with tumors that have already spread have a new chemotherapy-free treatment option. The FDA on Wednesday approved Lynparza, a PARP inhibitor from AstraZeneca (NYSE:AZN) and  Merck (NYSE:MRK)  that previously had been approved to treat people with ovarian and breast cancers.   Not surprising  The FDA completed its review of Lynparza for prostate cancer patients with tumors that test positive for homologous recombination repair (HRR) mutations a couple of months ahead of schedule. While the approval wasn't surprising, the FDA's decision came much more swiftly than expected. Image source: Getty Images. During the clinical trial that AstraZeneca and Merck ran to support Lynparza's label expansion, patients treated with Lynparza were 66% less likely to die or show signs of disease progression than those given Xtandi from Astellas Pharma and  Pfizer (NYSE:PFE) or Zytiga from Johnson & Johnson (NYSE:JNJ) . Anot

The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).   The Food and Drug Administration (FDA) has approved the targeted drug Lynparza (olaparib) for the treatment of men with metastatic castration-resistant prostate cancer that is driven by a homologous recombination repair (HRR) gene defect and has progressed following treatment with the novel hormonal drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).   Lynparza has the green light for use in treating these patients whether their HRR defect is inherited or acquired. HRR defects make it difficult for cancer cells to repair their DNA once it’s been damaged. Lynparza, part of a family of drugs known as PARP inhibitors, capitalizes on that weakness and further inh

Several new drugs have been approved for metastatic prostate cancer (PCa) since 2004, but declines in PCa screening due to a 2012 US Preventive Screening Task Force (USPSTF) recommendation against it may have eroded drug-related survival gains, according to investigators of a new study presented during the American Urological Association 2020 Virtual Experience. Michael Adam Feuerstein, MD, of Northwell Health in New York City, and colleagues analyzed data from 34,888 men (median age 72 years) with metastatic PCa from 18 Surveillance, Epidemiology, and End Results (SEER) registries to better understand disease trends. From 2004 to 2015, there was an uptick in de novo M1 diagnoses from 10.2 to 12.1 per 100,000. The incidence of PCa with bone metastasis with or without lymph node involvement (M1b) increased, whereas incidence of disease in non-regional lymph nodes (M1a) and distant metastatic disease (M1c) remained stable. Overall survival at 2 years for M1 disease increased only sl

The American Cancer Society estimates 191,930 men in 2020 will be told they have prostate cancer. Currently there are nearly 3.1 million American men living with the disease — roughly equal to the population of Chicago. It was also disclosed that 1 in 9 men will be diagnosed with prostate cancer in his lifetime and a startling statistic finds the incidence rate for this disease in military personnel increases to 1 in 5. Let me tell you about this disease and its’ impact upon our military veterans. A 2013 study conducted at the Portland VA Medical Center and Oregon Health and Science University found veterans of the Vietnam War, and other locations where exposure to Agent Orange (AO) occurred, are not only at higher risk for prostate cancer but they are more likely to have very aggressive forms of the disease. TCDD (tetrachlorodibenzo-P-dioxin), a dioxin chemical compound, was the most toxic portion of the AO mixture and this herbicide was used between 1962 and 1971 in the Vietnam W

A study of patients undergoing radical prostatectomy found that those chronic kidney disease or end-stage renal disease have a higher risk of 30- and 90-day readmission and 1-year mortality. Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) are at higher risk for worse postoperative outcomes after radical prostatectomy (RP) compared with patients without CKD, according to study findings presented at the American Urological Association 2020 Virtual Experience. In an analysis of 2009 to 2015 data from 23,014 RP patients New York State, Olamide Omidele, MD, and colleagues at the Icahn School of Medicine at Mount Sinai in New York found that CKD patients had significant 3.7-fold increased odds of a long hospital stay, 4.4-fold increased odds of both 30-day and 90-day hospital readmission, and nearly 3.3fold increased odds of 1-year mortality in adjusted analyses compared with patients without CKD. Patients with end-stage renal disease (ESRD) had nearly 1.8-

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) received approval from federal drug regulators to sell its Rubraca treatment for use in prostate-cancer patients. The Boulder pharmaceutical company said the drug will be available to prostate cancer patients who haven’t responded to chemotherapy or other existing forms of treatment. The drug was given priority review status in January for an Phase III trial in patients. “We are pleased that the FDA has granted an accelerated approval for Rubraca in this third indication,” CEO Patrick Mahaffy said in a statement. Rubraca, which was originally approved for use in 2016 for treating advanced ovarian cancer, is the only product Clovis has greenlit for sale. The company sold $143 million worth of Rubraca in 2019, a $47 million increase from the previous year.  

Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents on one of the most challenging complications and an independent predictor of global quality of life, post-prostatectomy incontinence.  Biographies: Diane K. Newman, DNP, ANP-BC, FAAN, Adjunct Professor of Urology in Surgery, Perelman School of Medicine, University of Pennsylvania and Co-Director of the Penn Center for Continence and Pelvic Health. She is the author of several books. The most recent is as lead editor of the 1st edition of the SUNA Core Curriculum for Urologic Nursing and of Clinical Application of Urologic Catheters, Devices, and Products.

Oliver Sartor, MD, head of Tulane Cancer Center’s Prostate Cancer Research Program, co-authored a study that revealed therapies based on tumor genetics may also show promise in treating some men with metastatic castration-resistant prostate cancer. (Photo by Paula Burch-Celentano) Prostate cancer therapies have shown significant advances during the past decade, with multiple new therapies being introduced for patients with advanced disease.  Now, the early results of a clinical trial published in the  New England Journal of Medicine  ( NEJM ) reveals for the first time that therapies based on tumor genetics – specifically DNA repair defects – may also show promise in treating some men with metastatic castration-resistant prostate cancer (mCRPC).  “This trial has shown a new breakthrough which I believe will lead to FDA approval,” said Oliver Sartor, MD, head of Tulane Cancer Center’s Prostate Cancer Research Program and a member of the Steering Committee that designed and imple